Converge Bio
AI platform for accelerated drug discovery and development
$25MSeries A
Role not disclosedSC
Saras Capital
Activity from announced rounds
Activity in this selectionAI · Series A
Saras Capital is the investor linked by Biographica, Converge and Shennon sources to Nadav Rosenberg.
Recorded funding activity
Biographica develops crop traits using AI discovery. Converge supplies drug-discovery models, while Shennon develops cancer therapies. These company records preserve separate biological applications and financing events.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $25M 1 disclosed · full round size, not this investor’s share